|Mr. Dan W. Gladney||Chairman, Chief Exec. Officer and Pres||463.72k||N/A||64|
|Dr. Mark B. Knudson Ph.D.||Co-Founder and Special Advisor to the CEO||N/A||N/A||68|
|Mr. Scott P. Youngstrom||Chief Financial Officer, Chief Compliance Officer and Sec.||65.42k||N/A||57|
|Mr. Peter M. DeLange MBA||Sr. VP of Operations and Bus. Devel.||283.15k||N/A||48|
|Mr. Paul F. Hickey||Sr. VP of Marketing and Reimbursement||282.8k||N/A||52|
EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The company develops the vBloc System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It has collaboration with Mayo Clinic. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.
EnteroMedics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.